Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Johann Wolfgang Goethe University of Frankfurt/Main, Hanau, Germany.
Menopause. 2010 Mar;17(2):426-40. doi: 10.1097/gme.0b013e3181c5159c.
The data of 69 cases of initially suspected black cohosh (BC)-induced liver disease were reviewed and analyzed to clarify whether BC hepatotoxicity really exists as a disease entity in these cases comparable to toxic liver disease being caused by various drugs and dietary supplements.
The cases comprised 11 published case reports and 58 spontaneous reports to national regulatory agencies. The analysis includes assessment of causality for BC, data quality of the presented cases, and their inconsistencies and confounding variables.
The assessed data raise serious doubts on the initial claims of causality for BC in these cases and provide clear evidence of their poor quality, especially when spontaneous reports are considered. There are major inconsistencies for the same patient regarding reported data. Moreover, the analysis of all cases disclosed confounding variables. These include poor case data quality, uncertainty of BC product, quality, and identification, undisclosed indication, insufficient adverse event definition, lack of temporal association and dechallenge, missing or inadequate evaluation of alcohol use, comedication, comorbidity, reexposure test, and alternative diagnoses.
The presented data do not support the concept of hepatotoxicity in a primarily suspected causal relationship to the use of BC and failure to provide a signal of safety concern, but further efforts have to be undertaken to dismiss or to substantiate the existence of BC hepatotoxicity as a special disease entity. The future strategy should be focused on prospective causality evaluations in patients diagnosed with suspected BC hepatotoxicity, using a structured, quantitative, and hepatotoxicity-specific causality assessment method.
对 69 例最初疑似黑升麻(BC)引起的肝病数据进行回顾和分析,以明确 BC 肝毒性是否真的存在于这些病例中,类似于各种药物和膳食补充剂引起的中毒性肝病。
这些病例包括 11 篇已发表的病例报告和 58 篇向国家监管机构自发报告的案例。分析包括对 BC 的因果关系评估、所提出案例的数据质量,以及它们的不一致性和混杂变量。
评估数据对这些案例中最初声称的 BC 因果关系提出了严重质疑,并提供了明确的证据,表明其数据质量差,特别是在考虑自发报告时。对于同一患者,报告的数据存在重大不一致性。此外,对所有案例的分析揭示了混杂变量。这些变量包括不良病例数据质量、BC 产品质量和鉴定的不确定性、未公开的适应症、不良反应定义不充分、缺乏时间关联和停药后观察、未报告或评估酒精使用、合并用药、合并症、再暴露测试和替代诊断。
所呈现的数据不支持 BC 肝毒性的概念,即在主要疑似因果关系下使用 BC 与安全性问题之间没有关联,但需要进一步努力排除或证实 BC 肝毒性作为一种特殊疾病实体的存在。未来的策略应侧重于对疑似 BC 肝毒性患者进行前瞻性因果关系评估,使用结构化、定量和肝毒性特异性的因果关系评估方法。